Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3289988 | 0.91 | SLC6A2 (0.57) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| SCHEMBL3293106 | 0.88 | SLC6A2 (0.71) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| SCHEMBL3288598 | 0.84 | SLC6A2 (0.74) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3289189 | 0.82 | SLC6A2 (0.77) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3292730 | 0.81 | SLC6A2 (0.77) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4055878 | 0.81 | SLC6A2 (0.77) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| SCHEMBL3599491 | 0.81 | SLC6A2 (0.77) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| SCHEMBL3605719 | 0.81 | SLC6A2 (0.77) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| SCHEMBL3289984 | 0.80 | SLC6A2 (0.73) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| SCHEMBL4059776 | 0.76 | SLC6A2 (0.67) | SLC6A2SLC6A3SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718652-B2 | Substituted benzothiadiazinedioxide derivatives and methods of their use | WYETH LLC (US) | 2010-05-18 | — | — | US | claimed |
| US-20080161295-A1 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | claimed |
| US-7718652-B2 | Substituted benzothiadiazinedioxide derivatives and methods of their use | WYETH LLC (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080161295-A1 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008073958-A2 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161295-A1 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A2, SLC6A4, DBH | SLC6A2 1/4885SLC6A3 4/4885SLC6A4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.